Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab for Pre-empting Graft Failure Post-Allo-HSCT
NCT04731298Phase 2Terminated
- Sponsor
- Sobi
- Start
- May 2021
- Primary completion
- Apr 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of emapalumab in Graft failure, sponsored by Sobi. Started May 2021; status: terminated.
02
Drugs
emapalumab
03
Conditions
Graft failure
Beyond the preview
Go deeper on NCT04731298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04731298.